Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT
暂无分享,去创建一个
N. Kröger | M. Labopin | P. Chevallier | D. Blaise | A. Nagler | M. Mohty | M. Itälä-Remes | B. Afanasyev | S. Mielke | G. Socié | Z. Perić | G. Helbig | P. Jindra | J. Tischer | S. Giebel | N. Shem-Tov | H. Labussière-Wallet | C. Peczynski | H. Labussière‐Wallet
[1] M. Labopin,et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT , 2018, Journal of Hematology & Oncology.
[2] L. Luznik,et al. Have haploidentical transplants replaced umbilical cord transplants for acute leukemias? , 2017, Current opinion in hematology.
[3] N. Kröger,et al. Post-Transplant Cyclophosphamide (PT-Cy) for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Transplantation from HLA Identical Sibling and Matched Unrelated Donor for Patients with Acute Leukemia, on Behalf of ALWP-EBMT , 2017 .
[4] A. Sun,et al. Haploidentical allogeneic hematopoietic stem cell transplantation compared to matched unrelated transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2017, Leukemia research.
[5] M. Labopin,et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT , 2017, Journal of Hematology & Oncology.
[6] C. Craddock,et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. , 2017, Blood advances.
[7] M. Labopin,et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant , 2017, Haematologica.
[8] A. Nademanee,et al. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] C. Craddock,et al. A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia , 2017, Journal of Hematology & Oncology.
[10] M. Labopin,et al. Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis , 2016 .
[11] Shannon R. McCurdy,et al. Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide , 2016 .
[12] J. Esteve,et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome–positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transpl , 2016, Cancer.
[13] J. Esteve,et al. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT , 2016, Haematologica.
[14] M. Labopin,et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission , 2016, Bone Marrow Transplantation.
[15] Yu Wang,et al. Haploidentical versus Matched-Sibling Transplant in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia: A Biologically Phase III Randomized Study , 2016, Clinical Cancer Research.
[16] R. Bouabdallah,et al. Haploidentical T Cell-Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen-Matched Related or Unrelated Donor. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] L. Luznik,et al. Modern approaches to HLA-haploidentical blood or marrow transplantation , 2016, Nature Reviews Clinical Oncology.
[18] R. Vij,et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. , 2015, Blood.
[19] A. Gennery,et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015 , 2015, Bone Marrow Transplantation.
[20] Ya-Zhen Qin,et al. Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] J. Sierra,et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia , 2015, Leukemia.
[22] U. Bayraktar,et al. "No donor"? Consider a haploidentical transplant. , 2015, Blood reviews.
[23] A. Gennery,et al. Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants , 2015, Bone Marrow Transplantation.
[24] C. Craddock,et al. The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood , 2014 .
[25] Loren Gragert,et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. , 2014, The New England journal of medicine.
[26] M. Labopin,et al. Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation , 2014, Bone Marrow Transplantation.
[27] W. Wiktor-Jedrzejczak,et al. Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice , 2014, Bone Marrow Transplantation.
[28] A. Messori,et al. Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or chemotherapy , 2013, Annals of Hematology.
[29] S. Richards,et al. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. , 2013, Blood.
[30] L. Luznik,et al. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. , 2012, Seminars in oncology.
[31] K. Kreuzer,et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. , 2012, Blood.
[32] P. Gaynon,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. ASBMT Position Statement. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[33] P. Gaynon,et al. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] R. Larson,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[35] B. Sandmaier,et al. Defining the intensity of conditioning regimens: working definitions. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[36] M. Tallman,et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin , 2006, Blood.
[37] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[38] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] M. Flowers,et al. Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[40] E D Thomas,et al. 1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.
[41] J. Burchenal,et al. Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.